Treatment strategies and mortality risk factors in patients with multidrug-resistant Acinetobacter baumannii pneumonia: A retrospective analysis.

Investigación Clínica 2026 Open access

Read full text
Authors: Lili Liu, Wen Lu, Gege Fang, Wei Zhang
DOI: 10.54817/ic.v67n1a08
Cited by: 0
References: 41

Abstract

This study aimed to investigate the determinants of drug resis-tance risk factors, 30-day all-cause mortality risk factors, and related clinical treatment strategies in patients with multidrug-resistant Acinetobacter bauman-nii (MDRAB) pneumonia. This retrospective study analyzed data from 168 pa-tients with MDRAB pneumonia and 141 patients with non-MDRAB pneumonia between February 2022 and February 2025. On the second day of admission, the severity of illness and use of carbapenems, tigecycline, etc., were higher in MDR-AB pneumonia patients than in non-MDRAB pneumonia patients (p

Fields of Study & Subjects

Antibiotic Resistance in Bacteria Nosocomial Infections in ICU Antibiotic Use and Resistance

Publication details

Journal / source
Investigación Clínica
Volume
67
Issue
1
Pages
108–108
Publication date
5 March 2026
Language
EN